January 27, 2006
Willkie client Teva Pharmaceutical Industries Ltd. announces that it has completed its acquisition of IVAX Corporation.
On January 26, Willkie client Teva Pharmaceutical Industries Ltd. announced that it has completed its acquisition of IVAX Corporation, in a transaction valued at approximately $8.5 billion. The deal, which was announced last July, creates a unique company that will be the global leader in generic pharmaceuticals and a major player in the global healthcare industry. The combined company, operating under the Teva name, will have a presence in over 60 countries with approximately 26,000 employees. Willkie’s multidisciplinary team advising Teva includes partners Peter Jakes (NY), Eduardo Fernandez (Paris), Cornelius Finnegan III (NY), Jeffrey Hochman (NY), Richard Reinhold (NY), William Rooney (NY), Marc van der Woude (Brussels) and Theodore Whitehouse (DC); special counsel Jonathan Konoff (NY) and Peter Haller (NY); special European counsel Valerie Landes (Brussels) and Carolina Wodtke (Frankfurt); and associates David Park (NY), Christopher Peters (NY), Sherally Munshi (NY), Jessica VanderVeen (NY), David Benner (NY), Rebecca Zimmer (NY), Scott Eisenberg (NY), Douglas Cordiano (NY) and Katherine Schroeder (NY).
